Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLChristin Schütz, Andreas Burchert, Tim H. Brümmendorf et al.|Leukemia|2017Cited by 106
Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid LeukemiaSabrina Inselmann, Andreas Burchert, Ying Wang et al.|Cancer Research|2018Cited by 21
Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski TrialAndreas Burchert, Christin Schütz, Sabrina Inselmann et al.|Blood|2015Cited by 9
Expression of the CTLA-4 ligand CD86 (B7.2) on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in chronic myeloid leukemiaAndreas Burchert, Christin Schütz, Sabrina Inselmann et al.|RWTH Publications (RWTH Aachen)|2016Cited by 0